2CBCB-NBOMe, or NBOMe-TCB-2, is a serotonin receptor modulator and cyclized phenethylamine. It is the NBOMe derivative of the psychedelic drug TCB-2 (2C-BCB).
Interactions
Pharmacology Pharmacodynamics 2CBCB-NBOMe acts as a potent and selective agonist of the serotonin 5-HT2A and 5-HT2C receptors, with an affinity (Ki) of 0.27nM at the human serotonin 5-HT2A receptor, similar to that of other drugs such as TCB-2, 25I-NBOMe, and Bromo-DragonFLY.
History 2CB2CB-NBOMe was first described in the scientific literature by the lab of David E. Nichols and colleagues in 2007. It was part of an ongoing research program focused on mapping of the specific amino acid residues responsible for ligand binding to the serotonin 5-HT2A receptor.
Society and culture Legal status Canada 2CBCB-NBOMe is not a controlled substance in Canada as of 2025.
United Kingdom
United States 2CBCB-NBOMe is a controlled substance in Vermont as of January 2016.
See also Cyclized phenethylamine Jimscaline TCB-2 Tomscaline
References
External links 2CBCB-NBOMe - Isomer Design